Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York

This article has been Reviewed by the following groups

Read the full article See related articles

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2021.12.07.21267431: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: Study design and sample collection: This study was approved by the NYULH Institutional Review Board, protocol numbers i21-00493 and i21-00561.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power AnalysisStatistical analysis: The comparison of 132 breakthrough and 283 unvaccinated control samples achieved 96% power in detecting a 15% difference (10% versus 25%) in mutation rates, clinical or demographic variables in a two-tailed chi squared/Fisher Exact test with a type I error of 5% (G*Power v.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    Statistical analysis: The comparison of 132 breakthrough and 283 unvaccinated control samples achieved 96% power in detecting a 15% difference (10% versus 25%) in mutation rates, clinical or demographic variables in a two-tailed chi squared/Fisher Exact test with a type I error of 5% (G*Power v.
    G*Power
    suggested: (G*Power, RRID:SCR_013726)
    The relationship between variant distribution and time since vaccination was studied using linear regression analyses in Prism v.
    Prism
    suggested: (PRISM, RRID:SCR_005375)

    Results from OddPub: Thank you for sharing your data.


    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    As with all observational genomic surveillance studies, limitations and confounding factors exist. These include demographic, temporal, and behavioral factors, diagnostic testing practices, sequencing sensitivity thresholds, and sampling, e.g., undersampling of mild or asymptomatic cases. Some but not all of these factors can be adjusted or minimized by unbiased sample collection, consistent testing procedures and guidelines, and matched data analyses. Our adjusted model indicates that the probability of Delta infection has increased at similar rates in vaccinated and unvaccinated individuals. However, Delta breakthrough cases appear to rise continuously with extended time post vaccination (Fig. 5), which justifies the use of booster doses 52,53. Monitoring Delta, its evolving subvariants, and newly emerging variants including their early signs of adaptive evolution will be critical to adequately address upcoming SARS-CoV-2 outbreaks and the increasing numbers of vaccine breakthrough infections.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a protocol registration statement.

    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.